Here’s whether Altimmune, Inc. Common Stock (ALT) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bearish.
🔴
Bearish
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.70% over 10 days); RSI 29 — oversold; weak 1-year return of -32.6%. Currently 57.0% off its 52-week high. Score: -6/7.
ALT is trading below its 200-day MA ($3.79) — a key warning sign the longer-term trend is under pressure. An RSI of 28.8 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -32.6% compares to +16.5% for SPY (trailed the market by 49.1%). The current 57.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $6,740 today
vs. S&P 500 (SPY) — same period trailed market by 49.1%